^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SBI-756

    i
    Other names: SBI-756, SBI-0640756
    Company:
    National Cancer Institute - Bethesda, Sanford-Burnham Medical Research Institute, TGen
    Drug class:
    AKT inhibitor, mTORC1 inhibitor, NF-κB inhibitor, eIF4G1 inhibitor
    Related drugs:
    24d
    Targeting eIF4G1-dependent translation in melanoma. (PubMed, bioRxiv)
    We previously identified SBI-756, a small molecule that interferes with the eIF4F assembly and overcomes melanoma resistance to BRAF inhibitors...Alone, M19-6 reduced melanoma growth and metastasis in a xenograft model. M19-6 offers a new therapeutic modality to overcome resistance and metastasis.
    Journal
    |
    EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1)
    |
    SBI-756
    almost3years
    Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition. (PubMed, Sci Rep)
    SBI-756, a small molecule inhibitor of eIF4F assembly, sensitizes human Ph+ and Ph-like B-ALL cells to dasatinib cytotoxicity without affecting survival of T lymphocytes or natural killer cells. These findings support the further evaluation of eIF4F-targeted molecules in combination therapies with TKIs in B-ALL and other blood cancers.
    Journal
    |
    EIF4G1 (Eukaryotic translation initiation factor 4 gamma, 1)
    |
    dasatinib • SBI-756